Literature DB >> 30739802

Myocardial viability of the peri-infarct region measured by T1 mapping post manganese-enhanced MRI correlates with LV dysfunction.

Yuko Tada1, Shahriar Heidary1, Atsushi Tachibana1, Junaid Zaman1, Evgenios Neofytou1, Rajesh Dash1, Joseph C Wu1, Phillip C Yang2.   

Abstract

BACKGROUND: Manganese-enhanced MRI (MEMRI) detects viable cardiomyocytes based on the intracellular manganese uptake via L-type calcium-channels. This study aimed to quantify myocardial viability based on manganese uptake by viable myocardium in the infarct core (IC), peri-infarct region (PIR) and remote myocardium (RM) using T1 mapping before and after MEMRI and assess their association with cardiac function and arrhythmogenesis.
METHODS: Fifteen female swine had a 60-minute balloon ischemia-reperfusion injury in the LAD. MRI (Signa 3T, GE Healthcare) and electrophysiological study (EPS) were performed 4 weeks later. MEMRI and delayed gadolinium-enhanced MRI (DEMRI) were acquired on LV short axis. The DEMRI positive total infarct area was subdivided into the regions of MEMRI-negative non-viable IC and MEMRI-positive viable PIR. T1 mapping was performed to evaluate native T1, post-MEMRI T1, and delta R1 (R1post-R1pre, where R1 equals 1/T1) of each territory. Their correlation with LV function and EPS data was assessed.
RESULTS: PIR was characterized by intermediate native T1 (1530.5 ± 75.2 ms) compared to IC (1634.7 ± 88.4 ms, p = 0.001) and RM (1406.4 ± 37.9 ms, p < 0.0001). Lower post-MEMRI T1 of PIR (1136.3 ± 99.6 ms) than IC (1262.6 ± 126.8 ms, p = 0.005) and higher delta R1 (0.23 ± 0.08 s-1) of PIR than IC (0.18 ± 0.09 s-1, p = 0.04) indicated higher myocardial manganese uptake of PIR compared to IC. Post-MEMRI T1 (r = -0.57, p = 0.02) and delta R1 (r = 0.51, p = 0.04) of PIR correlated significantly with LVEF.
CONCLUSIONS: PIR is characterized by higher manganese uptake compared to the infarct core. In the subacute phase post-IR, PIR viability measured by post-MEMRI T1 correlates with cardiac function.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Manganese-enhanced MRI; Myocardial infarction; Myocardial viability; T1 mapping

Mesh:

Year:  2019        PMID: 30739802      PMCID: PMC6434939          DOI: 10.1016/j.ijcard.2019.01.101

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  44 in total

1.  The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.

Authors:  Robert J Burns; Raymond J Gibbons; Qilong Yi; Robin S Roberts; Todd D Miller; Gary L Schaer; Jeffrey L Anderson; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2002-01-02       Impact factor: 24.094

2.  Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality.

Authors:  Andrew T Yan; Adolphe J Shayne; Kenneth A Brown; Sandeep N Gupta; Carmen W Chan; Tuan M Luu; Marcelo F Di Carli; H Glenn Reynolds; William G Stevenson; Raymond Y Kwong
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

3.  Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats.

Authors:  M Saeed; J Bremerich; M F Wendland; R Wyttenbach; H J Weinmann; C B Higgins
Journal:  Radiology       Date:  1999-10       Impact factor: 11.105

4.  Dobutamine-induced stress affects intracellular uptake of manganese: a quantitative magnetic resonance imaging study in pigs.

Authors:  Rolf Eriksson; Lars Johansson; Tomas Bjerner; Håkan Ahlström
Journal:  J Magn Reson Imaging       Date:  2005-04       Impact factor: 4.813

Review 5.  Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart.

Authors:  Michael F Wendland
Journal:  NMR Biomed       Date:  2004-12       Impact factor: 4.044

6.  Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging.

Authors:  H Arheden; M Saeed; C B Higgins; D W Gao; P C Ursell; J Bremerich; R Wyttenbach; M W Dae; M F Wendland
Journal:  Radiology       Date:  2000-05       Impact factor: 11.105

7.  Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media.

Authors:  M Saeed; G Lund; M F Wendland; J Bremerich; H Weinmann; C B Higgins
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

8.  Characterization of viable and nonviable myocardium at MR imaging: comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model.

Authors:  Sebastian Flacke; John S Allen; Jon M Chia; James H Wible; M Peri Periasamy; Max D Adams; I Kofi Adzamli; Christine H Lorenz
Journal:  Radiology       Date:  2003-01-24       Impact factor: 11.105

9.  Preliminary evaluation of EVP 1001-1: a new cardiac-specific magnetic resonance contrast agent with kinetics suitable for steady-state imaging of the ischemic heart.

Authors:  Pippa Storey; Peter G Danias; Mark Post; Wei Li; Peter R Seoane; Phillip P Harnish; Robert R Edelman; Pottumarthi V Prasad
Journal:  Invest Radiol       Date:  2003-10       Impact factor: 6.016

10.  Contrast-enhanced MR delineation of stunned myocardium with administration of MnCl(2) in rats.

Authors:  Gabriele A Krombach; Maythem Saeed; Charles B Higgins; Victor Novikov; Michael F Wendland
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

View more
  1 in total

1.  Assessment of Cardiac Toxicity of Manganese Chloride for Cardiovascular Magnetic Resonance.

Authors:  Elodie Lamonzie; Fanny Vaillant; Emma Abell; Sabine Charron; Dounia El Hamrani; Bruno Quesson; Fabien Brette
Journal:  Front Physiol       Date:  2022-07-07       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.